The forecasted data for malignant neoplasms of the trachea, bronchus, or lung in the US shows a consistent decline in mortality rates from 2024 to 2028. The year-on-year percentage decreases are as follows: 6.2% from 2024 to 2025, 6.3% from 2025 to 2026, 6.8% from 2026 to 2027, and 6.9% from 2027 to 2028. This delineates a progressively stronger downward trend. With the compounding average growth rate (CAGR) being approximately -6.55% annually over the forecasted five-year span, the decline reflects significant advances in healthcare, early diagnosis, or treatment effectiveness for these conditions.
Future trends to watch for include potential impacts of innovations in cancer treatment, changes in smoking rates, and advancements in genetic research. Public health initiatives and policy changes could also further influence these mortality rates positively.
